AKL THERAPEUTICS LIMITED

Active Manchester

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
A

AKL THERAPEUTICS LIMITED

Research and experimental development on biotechnology

Founded 20 Jan 2023 Active Manchester, England 0 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 15 Apr 2026 Next due 31 Oct 2026 5 months remaining
Confirmation Submitted 5 Jan 2026 Next due 19 Jan 2027 7 months remaining
Net assets £1 £0 2025 year on year
Total assets £1 £0 2025 year on year
Total Liabilities £0
Charges None No charges registered

Contact & Details

Contact

Registered Address

The Lexicon Second Floor Mount Street Manchester M2 5NT England

Full company profile for AKL THERAPEUTICS LIMITED (14606862), an active company based in Manchester, England. Incorporated 20 Jan 2023. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Feb → 31 Jan 2026
Type dormant
Next accounts 31 Jan 2026
Due by 31 Oct 2026 5 months remaining

Net Assets, Total Assets & Total Liabilities (2023–2025)

Cash in Bank

N/A

Net Assets

£1.00

Total Liabilities

N/A

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2026
31 Jan Year End
2025
31 Jan Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active
Status
David Richard SharplesDirectorBritishEngland7120 Jan 2023Active

Shareholders

Shareholders (1)

Akl Research & Development Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 20 Jan 2023
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

AKL THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
15 Apr 2026AccountsAnnual accounts made up to 31 Jan 2026
5 Jan 2026Confirmation StatementConfirmation statement made on 5 Jan 2026 with updates
15 Dec 2025Persons With Significant ControlChange to Akl Research & Development Limited as a person with significant control on 10 Dec 2025
4 Mar 2025AccountsAnnual accounts made up to 31 Jan 2025
24 Jan 2025Confirmation StatementConfirmation statement made on 9 Jan 2025 with no updates
15 Apr 2026 Accounts

Annual accounts made up to 31 Jan 2026

5 Jan 2026 Confirmation Statement

Confirmation statement made on 5 Jan 2026 with updates

15 Dec 2025 Persons With Significant Control

Change to Akl Research & Development Limited as a person with significant control on 10 Dec 2025

4 Mar 2025 Accounts

Annual accounts made up to 31 Jan 2025

24 Jan 2025 Confirmation Statement

Confirmation statement made on 9 Jan 2025 with no updates

Recent Activity

Latest Activity

Annual accounts made up to 31 Jan 2026

1 months ago on 15 Apr 2026

Confirmation statement made on 5 Jan 2026 with updates

4 months ago on 5 Jan 2026

Change to Akl Research & Development Limited as a person with significant control on 10 Dec 2025

5 months ago on 15 Dec 2025

Annual accounts made up to 31 Jan 2025

1 years ago on 4 Mar 2025

Confirmation statement made on 9 Jan 2025 with no updates

1 years ago on 24 Jan 2025